Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920555 · ClinicalTrials.gov registry record · Phase 2
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
A Phase 2 study of Treatment-Resistant Depression, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 6
- Study locations
NCT01920555: Completed Phase 2 study of Treatment-Resistant Depression, sponsored by Massachusetts General Hospital.
NCT01920555 is a Phase 2 study of Treatment-Resistant Depression that has completed, run by Massachusetts General Hospital. The registered enrollment target is 99 participants, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01920555, a Phase 2 study of Treatment-Resistant Depression, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
Primary Outcome
The HAMD6 is a 6-item clinician-rated scale, where clinicians rate the presence of depression symptoms (i.e., depressed mood, guilt, work and interests, psychomotor retardation, psychic anxiety, somatic symptoms) on a 5-point scale, where 0 = not present, and 1-4 represent increasingly severe symptoms. One item (i.e., somatic symptoms) is rated on only a 3-point scale, ranging from 0-2. The possible scale range is 0-22, where higher values represent more severe depression. This instrument is com
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Placebo Midazolam
Study Locations (6)
Texas
- University of Texas Southwestern - Dallas
- Baylor College of Medicine - Houston
California
- Stanford University - Palo Alto
Connecticut
- Yale University - New Haven
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
What the finished NCT01920555 record still lists
NCT01920555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT01920555 lists 6 locations in 5 states (Texas, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT01920555 about?
NCT01920555 is a clinical study titled "Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)". This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
What is the current status of trial NCT01920555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2014-12. Estimated completion is 2017-02.
What conditions does trial NCT01920555 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT01920555?
The interventions under investigation include: Ketamine (DRUG), Placebo Midazolam (DRUG).
Who is sponsoring clinical trial NCT01920555?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01920555 being conducted?
This trial has 6 study locations across California, Connecticut, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01920555's enrollment target sits among peer trials
99 19th of 54 higher than 36 of 54 other Treatment-Resistant Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
-
Psilocybin rTMS for Treatment Resistant Depression
RECRUITING · Phase 2
-
Antidepressant Effects of Nitrous Oxide
RECRUITING · Phase 2
-
Mindfulness Engaged Neurostimulation for Depression
RECRUITING · Phase 2
-
Neural and Antidepressant Effects of Propofol
ACTIVE NOT RECRUITING · Phase 2
-
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia